BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Selinexor: trial readouts and FDA decisions
2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Karyopharm Therapeutics Inc, US Oncology Research. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT02227251 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | active not recruiting | 244 |
| 2026-12 est. | P2/P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | active not recruiting | 501 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09 est. | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT04562870 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | Myelofibrosis | active not recruiting | 112 |
| 2026-05-31 est. | P2 | US Oncology Research | NCT04782687 Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | Multiple Myeloma; Myeloma Multiple; Kahler Disease; Myeloma, Plasma Cell; Myeloma-Multiple; Myelomat | active not recruiting | 73 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.